[go: up one dir, main page]

SE9901272D0 - New improved formulation - Google Patents

New improved formulation

Info

Publication number
SE9901272D0
SE9901272D0 SE9901272A SE9901272A SE9901272D0 SE 9901272 D0 SE9901272 D0 SE 9901272D0 SE 9901272 A SE9901272 A SE 9901272A SE 9901272 A SE9901272 A SE 9901272A SE 9901272 D0 SE9901272 D0 SE 9901272D0
Authority
SE
Sweden
Prior art keywords
new improved
improved formulation
pharmaceutical formulations
bisphosphonate
osteoporosis
Prior art date
Application number
SE9901272A
Other languages
Swedish (sv)
Inventor
Lennart Lindfors
Jan-Erik Loefroth
Sven Sjoegren
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9901272A priority Critical patent/SE9901272D0/en
Publication of SE9901272D0 publication Critical patent/SE9901272D0/en
Priority to AU41619/00A priority patent/AU4161900A/en
Priority to IL14550600A priority patent/IL145506A0/en
Priority to KR1020017012793A priority patent/KR20010104389A/en
Priority to CA002364659A priority patent/CA2364659A1/en
Priority to NZ514478A priority patent/NZ514478A/en
Priority to EP00921288A priority patent/EP1171097A1/en
Priority to JP2000610444A priority patent/JP2002541185A/en
Priority to PCT/SE2000/000664 priority patent/WO2000061111A1/en
Priority to ZA200108260A priority patent/ZA200108260B/en
Priority to NO20014895A priority patent/NO20014895L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.
SE9901272A 1999-04-09 1999-04-09 New improved formulation SE9901272D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (en) 1999-04-09 1999-04-09 New improved formulation
PCT/SE2000/000664 WO2000061111A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
CA002364659A CA2364659A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
IL14550600A IL145506A0 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
KR1020017012793A KR20010104389A (en) 1999-04-09 2000-04-06 A Pharmaceutical Formulation Comprising an Bisphosphonate and an Additive Agent Providing an Enhanced Absorption of the Bisphosphonate
AU41619/00A AU4161900A (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
NZ514478A NZ514478A (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
EP00921288A EP1171097A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
JP2000610444A JP2002541185A (en) 1999-04-09 2000-04-06 Pharmaceutical formulations comprising bisphosphonates and additives providing enhanced absorption of bisphosphonates
ZA200108260A ZA200108260B (en) 1999-04-09 2001-10-08 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate.
NO20014895A NO20014895L (en) 1999-04-09 2001-10-08 Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (en) 1999-04-09 1999-04-09 New improved formulation

Publications (1)

Publication Number Publication Date
SE9901272D0 true SE9901272D0 (en) 1999-04-09

Family

ID=20415159

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901272A SE9901272D0 (en) 1999-04-09 1999-04-09 New improved formulation

Country Status (11)

Country Link
EP (1) EP1171097A1 (en)
JP (1) JP2002541185A (en)
KR (1) KR20010104389A (en)
AU (1) AU4161900A (en)
CA (1) CA2364659A1 (en)
IL (1) IL145506A0 (en)
NO (1) NO20014895L (en)
NZ (1) NZ514478A (en)
SE (1) SE9901272D0 (en)
WO (1) WO2000061111A1 (en)
ZA (1) ZA200108260B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CN1446093A (en) * 2000-04-07 2003-10-01 得克萨斯系统大学董事会 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
EP1284754B1 (en) * 2000-05-05 2006-01-04 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
KR20030083725A (en) * 2001-03-01 2003-10-30 에미스페어 테크놀로지스, 인코포레이티드 Compositions for delivering bisphosphonates
AU2002330692A1 (en) 2001-07-02 2003-01-21 Elan Corporation, Plc. Delivery of a bioactive material
DE60317061T2 (en) 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag IBANDRONIC ACID FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
AU2003250218B2 (en) 2002-12-20 2006-10-26 F. Hoffmann-La Roche Ag High dose Ibandronate formulation
ES2311142T3 (en) * 2003-01-17 2009-02-01 Teva Pharmaceutical Industries Limited PROCEDURE TO REDUCE THE IRON CONTENT OF SODIUM RISEDRONATE.
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US8637503B2 (en) 2003-05-16 2014-01-28 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
MY144704A (en) * 2004-05-24 2011-10-31 Procter & Gamble Dosage forms of bisphosphonates
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
KR100815040B1 (en) * 2005-01-31 2008-03-18 주식회사종근당 Pharmaceutical Compositions for Improved Oral Absorption of Bisphosphonate Drugs
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
BRPI0710503A2 (en) 2006-04-07 2011-08-16 Merrion Res Iii Ltd use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
JP5671451B2 (en) 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド Compositions and preparation processes for GnRH related compounds
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
KR101631243B1 (en) * 2009-05-13 2016-06-17 신일제약주식회사 Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
FR2954320B1 (en) 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
JP2014501784A (en) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド Pharmaceutical composition of iron for oral administration
KR20120105738A (en) * 2011-03-16 2012-09-26 현대약품 주식회사 An enteric-coated oral formulation
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US20180161401A1 (en) * 2015-07-06 2018-06-14 Zheng Xin Dong Novel Formulations of PTHrP Analogue
WO2017195031A1 (en) * 2016-05-13 2017-11-16 Grunenthal Gmbh Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN112972400A (en) * 2021-03-09 2021-06-18 华侨大学 Rapidly disintegrable minodronic acid granules and preparation method thereof
KR102844771B1 (en) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
SE501389C2 (en) * 1992-04-24 1995-01-30 Leiras Oy Pharmaceutical preparation and process for its preparation
CA2162470C (en) * 1993-05-15 1998-06-16 Walter Preis Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
FI109088B (en) * 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
SE9703691D0 (en) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
AU4161900A (en) 2000-11-14
CA2364659A1 (en) 2000-10-19
JP2002541185A (en) 2002-12-03
NO20014895D0 (en) 2001-10-08
NZ514478A (en) 2004-01-30
IL145506A0 (en) 2002-06-30
KR20010104389A (en) 2001-11-24
WO2000061111A1 (en) 2000-10-19
ZA200108260B (en) 2003-03-26
EP1171097A1 (en) 2002-01-16
NO20014895L (en) 2001-12-10

Similar Documents

Publication Publication Date Title
SE9901272D0 (en) New improved formulation
SE9703691D0 (en) Pharmaceutical compositions
ATE232874T1 (en) PROSTAGLANDIN CONJUGATES FOR THE TREATMENT OF BONE DISEASES
BR0016058A (en) Phosphonate Compounds
TR200101103T2 (en) Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor
SI1663185T1 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
AR020345A1 (en) PIRAZOL-CARBOXANILIDS, PROCEDURE FOR OBTAINING, COMPOSITIONS, USE OF SUCH COMPOUNDS AND PROCEDURE FOR THE FIGHT AGAINST INDESEABLE MICROORGANISMS, AND PROCEDURE FOR OBTAINING SUCH COMPOSITIONS.
AP9901478A0 (en) Compounds for the treatment of ischemia.
SI1509232T1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
PT1235799E (en) POLYMORIC FORM OF ATORVASTATIN-CALCIUM
HUP0004271A2 (en) Compositions comprising amylin or amylin agonist for treating obesity
DK0679393T3 (en) Pharmaceutical composition for the treatment of osteoporosis containing xanthohumol
DE50004334D1 (en) DESODORIOUS PREPARATIONS CONTAINING WATER-SOLUBLE - (1,3) -GLUCANE
TR199902703T2 (en) Protease inhibitors.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
ID18079A (en) PHARMACEUTICAL COMPOSITION THAT CONTAINS FASTEST OSTEOGENESIS
DE69905214D1 (en) Agents for the treatment of osteoporosis
DE69730796D1 (en) Naphthyl compounds, compositions and methods
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
ATE305517T1 (en) NEUROTRYPSIN
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
DE69723639D1 (en) Benzothiophene compounds, preparations and methods
DE69916326D1 (en) MEDICAL COMPOSITIONS FOR TREATING BONE DAMAGE IN MULTIPLE MYELOMA
ATE244230T1 (en) DIHYDROBENZOFLUORENE COMPOUNDS, INTERMEDIATE PRODUCTS, COMPOSITIONS AND METHOD
FR2783518B1 (en) LTA4 HYDROLASE INHIBITORS